Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. The International Antimicrobial Therapy Project Group of the European Organization for Research and Treatment of Cancer
- PMID: 6366126
- DOI: 10.1200/JCO.1983.1.10.597
Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. The International Antimicrobial Therapy Project Group of the European Organization for Research and Treatment of Cancer
Abstract
A total of 841 febrile neutropenic patients from 20 centers were randomized to receive carbenicillin (or ticarcillin) plus amikacin or these antibiotics plus cefazolin to compare outcome and incidence of nephrotoxicity. Infection with Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, or Staphylococcus aureus accounted for most of the microbiologically documented febrile episodes. The response to therapy was similar in the two treatment groups for all infections and for bacteremia. Improvement occurred in 35 (64%) of 55 bacteremic patients treated with two antibiotics and 39 (65%) of 60 treated with three antibiotics. An increase in serum creatinine to 2 mg/dL over baseline occurred in eight (2.1%) of 381 patients in the former and in 50 (2.4%) of 364 patients in the latter group. Thus, the two antibiotic regimens were equal in efficacy and in nephrotoxicity. Although not the primary focus of this study, a significant decrease in incidence of infection, including bacteremias, was found in neutropenic patients treated with any oral intestine decontamination regimen.
Similar articles
-
In vitro models for the study of combination antibiotic therapy in neutropenic patients.Am J Med. 1986 Jun 30;80(6B):156-60. doi: 10.1016/0002-9343(86)90494-8. Am J Med. 1986. PMID: 3728526
-
Piperacillin plus amikacin therapy v carbenicillin plus amikacin therapy in febrile, granulocytopenic patients.Arch Intern Med. 1982 Sep;142(9):1663-7. Arch Intern Med. 1982. PMID: 6214228 Clinical Trial.
-
A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.Am J Med. 1986 May 30;80(5C):101-11. Am J Med. 1986. PMID: 3521269 Clinical Trial.
-
Empiric therapy of febrile granulocytopenic patients.Am J Hosp Pharm. 1979 Feb;36(2):178-87. Am J Hosp Pharm. 1979. PMID: 369364 Review.
-
Empiric treatment of infections in neutropenic patients with cancer.Rev Infect Dis. 1983 Mar-Apr;5 Suppl 1:S21-31. doi: 10.1093/clinids/5.supplement_1.s21. Rev Infect Dis. 1983. PMID: 6342096 Review.
Cited by
-
Empiric antimicrobial therapy in febrile granulocytopenic patients. Randomized prospective comparison of amikacin plus piperacillin with or without parenteral trimethoprim/sulphamethoxazole.Infection. 1986 Nov-Dec;14(6):261-7. doi: 10.1007/BF01643959. Infection. 1986. PMID: 3546144 Clinical Trial.
-
Cost analysis of 2 empiric antibacterial regimens containing glycopeptides for the treatment of febrile neutropenia in patients with acute leukaemia.Pharmacoeconomics. 1999 Jan;15(1):85-95. doi: 10.2165/00019053-199915010-00006. Pharmacoeconomics. 1999. PMID: 10345160 Clinical Trial.
-
Empiric treatment of infection during granulocytopenia: a comprehensive approach.Infection. 1989 Mar-Apr;17(2):59-64. doi: 10.1007/BF01646877. Infection. 1989. PMID: 2654018 Review. No abstract available.
-
Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations.Drugs. 1997 May;53(5):789-804. doi: 10.2165/00003495-199753050-00005. Drugs. 1997. PMID: 9129866 Review.
-
Infections in cancer patients: some controversial issues.Support Care Cancer. 1994 Mar;2(2):94-104. doi: 10.1007/BF00572090. Support Care Cancer. 1994. PMID: 8156272 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical